Evidence map›Paper›PMID 29699510›Full record

ArticleBMC cancer2018

Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.

Licun Wu, Walter Blum, Chang-Qi Zhu, Zhihong Yun, Laszlo Pecze, Mikihiro Kohno, Mei-Lin Chan, Yidan Zhao, Emanuela Felley-Bosco, Beat Schwaller and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Licun WuDivision of Thoracic Surgery, Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada.
Walter BlumDepartment of Medicine, Unit of Anatomy, University of Fribourg, CH-1700, Fribourg, Switzerland.
Chang-Qi ZhuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Zhihong YunDivision of Thoracic Surgery, Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada.
Laszlo PeczeDepartment of Medicine, Unit of Anatomy, University of Fribourg, CH-1700, Fribourg, Switzerland.
Mikihiro KohnoDivision of Thoracic Surgery, Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada.
Mei-Lin ChanDivision of Thoracic Surgery, Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada.
Yidan ZhaoDivision of Thoracic Surgery, Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada.
Emanuela Felley-BoscoLaboratory of Molecular Oncology, University Hospital Zurich, University of Zurich, 8044, Zürich, Switzerland.
Beat SchwallerDepartment of Medicine, Unit of Anatomy, University of Fribourg, CH-1700, Fribourg, Switzerland.
Marc de PerrotDivision of Thoracic Surgery, Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada. marc.deperrot@uhn.ca.
University Health Network · CAUniversity of Fribourg · CHPrincess Margaret Cancer Centre · CAUniversity of Zurich · CH

Funding

Mesothelioma Applied Research Foundation (MARF, USA) n/aMesothelioma Research Foundation (Canada) n/aPrincess Margaret Hospital Foundation (Canada) n/aSwiss National Science Foundation (SNF) Sinergia CRSII3 #147697
6 · The paper itself

Abstract

backgroundCancer cell repopulation during chemotherapy or radiotherapy is a major factor limiting the efficacy of treatment. Cancer stem cells (CSC) may play critical roles during this process. We aim to demonstrate the role of mesothelioma stem cells (MSC) in treatment failure and eventually to design specific target therapies against MSC to improve the efficacy of treatment in malignant mesothelioma.

methodsMurine mesothelioma AB12 and RN5 cells were used to compare tumorigenicity in mice. The expression of CSC-associated genes was evaluated by quantitative real-time PCR in both cell lines treated with chemo-radiation. Stemness properties of MSC-enriched RN5-EOS-Puro2 cells were characterized with flow cytometry and immunostaining. A MSC-specific gene profile was screened by microarray assay and confirmed thereafter. Gene Ontology analysis of the selected genes was performed by GOMiner.

resultsTumor growth delay of murine mesothelioma AB12 cells was achieved after each cycle of cisplatin treatment, however, tumors grew back rapidly due to cancer cell repopulation between courses of chemotherapy. Strikingly, a 10-times lower number of irradiated cells in both cell lines led to a similar tumor incidence and growth rate as with untreated cells. The expression of CSC-associated genes such as CD24, CD133, CD90 and uPAR was dramatically up-regulated, while others did not change significantly after chemoradiation. Highly enriched MSC after selection with puromycin displayed an increasing GFP-positive population and showed typical properties of stemness. Comparatively, the proportion of MSC significantly increased after RN5-EOS parental cells were treated with either chemotherapy, γ-ray radiation, or a combination of the two, while MSC showed more resistance to the above treatments. A group of identified genes are most likely MSC-specific, and major pathways related to regulation of cell growth or apoptosis are involved. Upregulation of the gene transcripts Tnfsf18, Serpinb9b, Ly6a, and Nppb were confirmed.

conclusionPutative MSC possess the property of stemness showing more resistance to chemoradiation, suggesting that MSC may play critical roles in cancer cell repopulation. Further identification of selected genes may be used to design novel target therapies against MSC, so as to eliminate cancer cell repopulation in mesothelioma.

Indexed as

AnimalsCell Line, TumorCell SurvivalChemoradiotherapyComputational BiologyDisease Models, AnimalDrug Resistance, NeoplasmFlow CytometryGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMesotheliomaMiceNeoplastic Stem CellsRadiation ToleranceCancer cell repopulationChemoradiationMesothelioma stem cell (MSC)MicroarrayRN5-EOS-Puro2 cells

Identifiers

PMID29699510
PMCPMC5921988
OpenAlexW2801673557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.